{"groups":[{"description":"R-CHOP: Patients receive R-CHOP every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses. Patients achieving a partial response, uncertain CR, or stable disease receive 4 additional courses. Patients are evaluated 3 weeks after the last course of therapy. Patients with progressive disease go off study.\n\nZevalin™Radioimmunotherapy: Beginning no more than 9 weeks after the last course of R-CHOP, patients receive rituximab IV on day 1 followed by indium In 111 ibritumomab tiuxetan IV over 10 minutes for imaging studies. Patients then receive rituximab IV followed by yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes on day 8.\n\nRadiotherapy: Patients with residual disease by CT scan or positron emission tomography (PET) scan after 12 weeks after radioimmunotherapy undergo conventional involved-field radiotherapy.","id":"FG000","title":"Treatment"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"9"}],"type":"Patient ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Insurance company refused to cover"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"62"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"53"}],"type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"48"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"14"}],"type":"NOT COMPLETED"}],"title":"Step 1 - R-CHOP"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"8"}],"type":"Patient ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Other"}],"milestones":[{"achievements":[{"comment":"This includes all patients who received step 2 treatment regardless of eligibility.","groupId":"FG000","numSubjects":"56"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"48"}],"type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"45"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Step 2 - Zevalin™ Radioimmunotherapy"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Step 3 - Radiation Therapy"}]}